SBRT + nimotuzumab + tislelizumab

This is a combination therapy consisting of stereotactic body radiotherapy (SBRT), nimotuzumab, and tislelizumab. - **SBRT** is a form of highly precise external radiation therapy that delivers high doses of radiation to tumors in a small number of fractions, minimizing exposure to surrounding healthy tissue. It is used primarily for localized solid tumors. - **Nimotuzumab** is a humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR). By binding EGFR, it inhibits downstream signaling pathways involved in tumor cell proliferation and survival. - **Tislelizumab** is an anti-programmed death receptor 1 (PD-1) monoclonal antibody developed by BeiGene. It blocks PD-1 interaction with its ligands PD-L1/PD-L2 on tumor cells, thereby restoring T-cell function and enhancing immune-mediated antitumor activity[1][2][4]. Tislelizumab has been approved for several indications including esophageal squamous cell carcinoma, gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, urothelial carcinoma, hepatocellular carcinoma, Hodgkin lymphoma[6][8][10]. This combination aims to leverage the local control provided by SBRT with the systemic antitumor effects of EGFR inhibition (nimotuzumab) and immune checkpoint blockade (tislelizumab).

Other names

SBRT plus nimotuzumab plus tislelizumabSBRT and nimotuzumab and tislelizumab